Business News • PR NewsWire • Xencor Presents Preliminary Data from an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-Related Disease (IgG4-RD) at the American College of Rheumatology 2016 Annual Meeting

Xencor Presents Preliminary Data from an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-Related Disease (IgG4-RD) at the American College of Rheumatology 2016 Annual Meeting

Xencor Presents Preliminary Data from an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-Related Disease (IgG4-RD) at the American College of Rheumatology 2016 Annual Meeting

MONROVIA, Calif., Nov. 13, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced preliminary data from...

View More : http://www.prnewswire.com/news-releases/xencor-presents-preliminary-data-from-an-ongoing-open-label-phase-2-study-of-xma...

Releted News by prnewswire

Hail Restore Explains Dent Repair in Oklahoma City, Oklahoma

From Such Wood Are World Champions Hewn

DarkMatter to Mark First Anniversary of Public Unveiling of Brand With Strong Presence at RSA Conference Abu Dhabi 2016